19 Aug, 2021 RNAi Roundtable: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1
Posted at 09:30h
in Capella
On August 19, 2021, we hosted an online RNAi Roundtable to review the progress with lumasiran, for the treatment of primary hyperoxaluria type 1.
Access the replay
View the presentation
Read the transcript
Jerome Valkenburg, MS, MScBA
Sr. Director & Program Lead, Lumasiran
Jeffrey M. Saland, M.D., MSCR
Professor, Icahn School of Medicine at Mount Sinai
John Gansner, M.D., Ph.D.
Director, Clinical Research
